Cell Genesys CEGE Parkison's Disease Trial

Today, 5/27/09, Cell Genesys, Inc. (CEGE) is out with some additional data on their Parkinson's Disease phase 2 clinical trial. CEGE is part owner of the company Ceregene. CEGE stock is ripping high in pre market to $0.55 Up 31%. Keep an eye on this penny stock today! Discuss CEGE

Cell Genesys News - May 27, 2009

Ceregene Presents Additional Clinical Data from Phase 2 Trial of CERE-120 for Parkinson's Disease

Ceregene, Inc. today reported additional clinical data from a double-blind, controlled Phase 2 trial of CERE-120 in 58 patients with advanced Parkinson's disease. CERE-120 uses AAV-based gene therapy to deliver the neurotrophic factor, neurturin, to Parkinson's disease patients in order to restore the function and protect degenerating nigrostriatal neurons. The company previously announced that the Phase 2 trial did not meet its primary endpoint of improvement in the Unified Parkinson's Disease Rating Scale (UPDRS) motor off score at 12 months of follow-up, although several secondary endpoints suggested a modest clinical benefit.

Full Article Here

For the latest updates on the stock market, visit, http://daytradingstockblog.blogspot.com/ or Subscribe for Free